New PET tracer could reveal hidden cancer clues without a biopsy

NCT ID NCT07459192

Not yet recruiting Diagnosis Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new radioactive tracer called 68Ga-DOTA-BLP for PET scans to see PD-L1 levels in tumors. PD-L1 helps cancer hide from the immune system, and knowing its levels can guide immunotherapy. The study will include 50 adults with confirmed cancer and suspicious spots on scans. The goal is to see if this imaging method is accurate and safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-DOTA-BLP (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a more accurate, non-invasive way to see PD-L1 levels in tumors, helping doctors choose the right immunotherapy for each patient.
What could go wrong: This is a small, early-stage study (50 people) that hasn't started yet. The new imaging method may not be more accurate than existing tests, and results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates